fda compounding semaglutide enforcement news november 2025 The has announced that it has given us an expedited review of the once-a-day weight loss pill we're investigating, potentially giving people living with obesity a new treatment option early next Diabetes advocacy group discourages use

Diabetes 72 , 599610 (2023)

Direct comparison helps inform decisions about which approach might work best for individual circumstances

Some insurance plans require prior authorization before approval

Table of Contents Why GLP-1 Medications May Cause Increased Urination Common Urinary Side Effects of GLP-1 Receptor Agonists When Frequent Urination on GLP-1 Treatment Needs Medical Attention Managing Increased Urination While Taking GLP-1 Medications Other Factors That May Affect Urination During GLP-1 Therapy Scientific References Frequently Asked Questions Why GLP-1 Medications May Cause Increased Urination GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), are increasingly prescribed for type 2 diabetes management and weight loss

Approved medicines have prescribing labels, pharmacy supply chains, adverse-event reporting systems, and post-marketing safety information

The incidence of vomiting was 13% with dulaglutide at 1.5 mg, 8% at 0.75 mg, and 2% with sitagliptin